Novel Telomere Regulation Technology

Background

Telomeres, protective caps at the ends of chromosomes, play a crucial role in maintaining cellular health. Their length is a key determinant of a cell's ability to replicate. Shortened telomeres, due to genetic mutations or acquired environmental insults, lead to telomerase dysfunction. This has been implicated in life-threatening diseases such as dyskeratosis congenita, aplastic anemia, pulmonary fibrosis, hepatic cirrhosis, and certain cancers. Currently, the standard of care involves symptomatic treatment and lifestyle modifications aimed at preventing further damage, but these approaches fail to address the underlying telomere dysfunction directly. The market is in urgent need of therapies that can effectively restore telomere length, impacting millions worldwide.

Technology Overview

From the lab of Dr. Suneet Agarwal, the disclosed inventions introduce innovative approaches targeting telomere regulation through two distinct mechanisms:

1. PAPD5 Inhibition: Novel small molecule inhibiting PAP Associated Domain Containing 5 (PAPD5), restoring Telomerase RNA Component (TERC) levels, enhancing telomerase activity, and promoting telomere elongation. This strategy directly addresses telomerase dysfunction at the genetic level.
   1. Project Status: Lead Optimization

2. Thymidine Metabolism Pathway: Research conducted by Boston Children’s Hospital has identified thymidine nucleotide metabolism as a critical pathway in controlling telomere length. Enhanced levels of thymidine nucleotide correlate with increased telomere length. Inhibition of SAMHD1, a thymidine nucleotide-degrading protein, using small molecule drugs, shRNAs, or CRISPR/Cas9, results in prolonged thymidine nucleotide lifespan and consequential telomere elongation. This approach offers a novel intervention method for neurodegenerative and premature aging-related diseases.

Boston Children’s is currently running a Phase 1 clinical trial for this technology: Nucleoside Therapy in Patients with Telomere Biology Disorders

Both technologies aim to provide therapeutic interventions against conditions linked to accelerated telomere shortening.

Applications

• Treatment of disorders associated with telomere dysfunction (e.g., dyskeratosis congenital, aplastic anemia)
• Management of aging-related degenerative diseases
• Pre-leukemic or pre-cancerous condition treatment
• Viral infections including HBV, HAV, and CMV
• Neurodevelopmental disorders linked to telomere dysfunction
• Enhancement of stem cell therapies via ex vivo expansion

Advantages

• Dual approach to telomere restoration through PAPD5 inhibition and thymidine pathway intervention
• Offers potential reduction or reversal of aging-related cellular degeneration
• Addresses the root causes of diseases tied to telomere dysfunction
• Provides innovative alternatives to current therapies which primarily manage symptoms
• May enhance stem cell therapy effectiveness through improved telomere stability

By combining insights from cellular biology and targeted genetic therapies, these technologies promise significant advancements in treating diseases traditionally deemed untreatable, offering renewed hope for enhancing quality and longevity of life.